Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin 2.5 mg vs 5 mg for benign prostatic hyperplasia
KCT0005531Phase 4Not yet recruiting
- Sponsor
- Il-Yang Pharmaceutical
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of terazosin in benign prostatic hyperplasia (BPH), sponsored by Il-Yang Pharmaceutical. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
terazosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on KCT0005531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005531.